GnRH Inhibitors
1 drugsAbout GnRH
Gonadotropin-releasing hormone (GnRH) is a peptide hormone that stimulates the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland, regulating gonadal function. It plays a central role in the reproductive system.
GnRH is a therapeutic target in oncology, modulating the GnRH receptor to control downstream hormonal signaling. Currently, there is no genetic evidence directly linking GnRH to specific diseases.
GnRH is targeted by one FDA-approved peptide drug, ZOLADEX (TERSERA), approved in 1989 for oncology indications. TERSERA is the leading company in this space.
Strategic Insights
ℹ️ How we calculate- Validated target with strong trial activity and 80% attractiveness score.
- White space opportunity in Anatomic Stage I Breast Cancer AJCC v8 with only 2 trials.
- phase4 represents biological uncertainty with 50% completion.
Top Drugs
The competitive landscape is highly concentrated, with TERSERA as the leading company.
High market concentration suggests significant entry barriers; consider strategic partnerships or niche indications.
Drug Modality Landscape
Modalities
Routes of Administration
GnRH is primarily targeted by small molecule modalities (92% of approved drugs).
Explore non-peptide modalities to differentiate from existing therapies and potentially improve drug properties.
📈 Modality Evolution
Small molecules pioneered GnRH targeting (1989), with peptides entering more recently (1989).
Clinical Trials 129 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 23 | 18 | 2 | 3 | 90% |
| Phase 2 | 61 | 27 | 12 | 22 | 69% |
| Phase 3 | 34 | 18 | 6 | 10 | 75% |
| Phase 4 | 11 | 4 | 4 | 3 | 50% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
2 Phase 3 trials testing approved GnRH drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting GnRH. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
Drug Approval Timeline (1989 - 2021)
The first and most recent drug approval for GnRH was ZOLADEX in 1989.
The lack of recent approvals indicates a saturated market or challenges in developing new GnRH-targeting drugs.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 92 clinical trials targeting GnRH.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities